They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.
Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.
The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.
In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.
Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.
The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.
The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.
In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.
The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
The Swiss Broadcasting Corporation (SBC), Swissinfo's parent company, must restructure due to financial pressures and to stay competitive in the fast-moving media environment.
This content was published on
There has been a sharp decline in the consumption of single-use disposable plastic bags and reusable plastic bags in the Swiss retail sector.
This content was published on
A biometric Swiss identity card (ID) is expected to be available in Switzerland by the end of 2026. The Federal Office of Police and its federal and cantonal partners are working on a new ID card that features a chip.
Heatwave reduces output at Swiss nuclear power plant by 50%
This content was published on
The ongoing heatwave has forced the Beznau nuclear power plant, which relies on water from the River Aare, to halve its output.
Swiss continue to enjoy high social mobility, study shows
This content was published on
Opportunities for upward social mobility have remained intact in Switzerland since the 1980s. Social mobility is exceptionally high by international comparison, a study shows.
Swiss government affected by cyberattack on health foundation
This content was published on
Switzerland says a ransomware attack on the non-profit health foundation Radix that involved data being stolen and encrypted had also affected the federal administration.
Federal Council agrees to investigation into alleged Swiss-Russian spying affair
This content was published on
The Office of the Attorney General of Switzerland can open spying investigations into the Swiss Federal Intelligence Service (FIS).
Appeal launched against Starlink satellite antennae project planned in Swiss village
This content was published on
A group of Swiss citizens has filed an appeal against plans to install 40 Starlink satellite antennae in the mountain village of Leuk in southern Switzerland.
UBS launches buyback scheme for up to $2 billion in shares
This content was published on
UBS is starting a share buyback programme for up to $2 billion (CHF1.6 billion) in shares, in line with a plan approved at its annual general meeting (AGM) in April, the Swiss bank said on Monday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis and Microsoft to develop drugs using AI
This content was published on
Novartis and Microsoft have signed a five-year partnership aimed at transforming the Basel-based pharma’s business using AI.
Gaps found in opioid prescription oversight in Switzerland
This content was published on
In the wake of the opioid crisis in the US, some medical professionals in Switzerland are warning about over-prescription of oxycodone drugs.
Swiss pharmaceutical firm lets dogs die cruel death
This content was published on
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, says a report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.